Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. It develops solutions to preserving vision and improve eye health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. It also develops NCX 4251, an investigational ophthalmic treatment based on fluticasone propionate that is in Phase 2 clinical trial for the treatment of dry eye disease; and NCX 1728, a NO-donating phosphodiesterase-5 inhibitor, which is in preclinical evaluation. In addition, the company offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching related associated with allergic conjunctivitis. Nicox S.A. was founded in 1996 and is headquartered in Biot, France.…
Nicox réduit sa perte semestrielle à 0,5 M€ grâce à un paiement de Kowa
Nicox (EPA: ALCOX) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 5 employees.
The shares were at 0.2600 EUR on 20 November 2026, down 13.3% over 52 weeks. Its 52-week range is 0.2520 EUR to 0.5690 EUR: the price is 54.3% below the high and 3.2% above the low.
At a market capitalisation of 26.47M EUR, it trades at 3.0 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 91% for ALCOX.
Nicox reports return on equity of -40.1%, an operating margin of 57.2% and revenue up 132.2% year over year.
It holds more cash than debt, a net cash position of 3.07M EUR. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. One analyst covers the stock; their mean price target of 1.000 EUR is 284.6% above the current price.